Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 3)
The aim of the study is to assess the treatment effects of deep active repetitive transcranial magnetic stimulation (rTMS) with H4 coil combined with cognitive training for improving frontal white matter microstructural integrity in patients with schizophrenia spectrum disorder (SSD).
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Schizophrenia is a severe mental illness that affects about 1% of the population but a major source of disability. Information processing between brain regions occurs due to transfer of electrical impulses among them. This process is determined by the existing neuronal/fiber connections, which may be altered and or modified in the presence of neuronal stimulation or cognitive intervention. The frontal lobe information flow is critical for higher cognitive functions, thought processes, and proper emotional and behavioral responses. Improving the myelination in the frontal lobe may increase cognitive functions and reduce risks to develop symptoms of schizophrenia. The investigators propose that increasing electrical signaling in the frontal white matter in patients with schizophrenia may also enhance myelination and improve the white matter integrity.
rTMS with H coil is FDA-cleared for short-term smoking cessation in the general population. The efficacy of its combination with cognitive training in myelination modulation has not been evaluated.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Xiaoming Du, PhD
- Telefonnummer: 443-882-9717
- E-post: Xiaoming.Du@uth.tmc.edu
Studer Kontakt Backup
- Navn: Bhim M Adhikari
- Telefonnummer: 713-486-2740
- E-post: bhim.m.adhikari@uth.tmc.edu
Studiesteder
-
-
Texas
-
Houston, Texas, Forente stater, 77054
- The University of Texas Health Science Center, Houston
-
Ta kontakt med:
- Xiaoming Du, PhD
- Telefonnummer: 443-882-9717
- E-post: Xiaoming.Du@uth.tmc.edu
-
Ta kontakt med:
- Bhim Adhikari
- Telefonnummer: 713-486-2740
- E-post: bhim.m.adhikari@uth.tmc.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male and female ages between ages 18-60 years
- Ability to give written informed consent (age 18 or above)
- Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.
Exclusion Criteria:
- Inability to sign informed consent.
- Any history of seizures.
- Any acute and unstable major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, recent stroke, seizure, history of significant head trauma, CNS infection or tumor, other significant brain neurological conditions (As this is a study of medical comorbidity, most medical conditions, once stable, are not exclusion criteria).
- Taking > 400 mg clozapine/day and not on anti-seizure medication(s) with sufficient dose.
- Failed TMS screening questionnaire.
- Significant alcohol or other drug use (substance abuse within 1 month or substance dependence history within 6 months and having substance usage within 1 month) other than nicotine or marijuana dependence.
- A history of thrombosis, family history of thrombosis, or medical conditions that may lead to a hypercoagulable state (increased chance to develop blood clots)
- Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive urine pregnancy test).
- History of head injury with loss of consciousness over 10 minutes; history of brain surgery
- Cannot refrain from using alcohol and/or marijuana 24 hours or more prior to experiments.
- Students and employees currently involved with our lab (lab employees and personnel will be excluded from the study to avoid possible coercion or possible appearance of coercion, or chance of breach of privacy and confidentiality).
- For MRI, unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts) or claustrophobic to the scanner.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Active rTMS Combined with Strong Cognitive Training
Participants will receive active H-coil delivered rTMS, as well as strong cognitive training in each treatment visit for up to 10 treatment visits within about 2 weeks. In each visit, there are three rTMS sessions and each of them is followed by a cognitive training session and a rest period, which allows the inter-rTMS-session interval to be about 30 minutes. The cognitive training includes several cognitive computer games that are meant to improve the speed and accuracy of performance--strong cognitive training is intended to significantly enhance cognitive functions. |
Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 10 visits within about 2 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete. For the cognitive training sessions, patients will be asked to play cognitive computer games involving processing speed tasks for about 15 to 30 minutes. Strong cognitive training is intended to significantly enhance cognitive functions |
|
Eksperimentell: Active rTMS Combined with Weak Cognitive Training
Participants will receive active H-coil delivered rTMS, as well as weak cognitive training in each treatment visit for up to 10 treatment visits within about 2 weeks. In each visit, there are three rTMS sessions and each of them is followed by a cognitive training session and a rest period, which allows the inter-rTMS-session interval to be about 30 minutes. The cognitive training includes several cognitive computer games that are meant to improve the speed and accuracy of performance--weak cognitive training may yield only modest improvements in cognitive functions. |
Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 10 visits within about 2 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete. For the cognitive training sessions, patients will be asked to play cognitive computer games involving processing speed tasks for about 15 to 30 minutes. Weak cognitive training may yield only modest improvements in cognitive functions. |
|
Eksperimentell: Sham rTMS Combined with Strong Cognitive Training
Participants will receive sham H-coil delivered rTMS, as well as strong cognitive training in each treatment visit for up to 10 treatment visits within about 2 weeks. In each visit, there are three rTMS sessions and each of them is followed by a cognitive training session and a rest period, which allows the inter-rTMS-session interval to be about 30 minutes. In case of sham TMS, no actual magnetic stimulation will occur, still the participant hears the TMS sound and a skin sensation. The cognitive training includes several cognitive computer games that are meant to improve the speed and accuracy of performance--strong cognitive training is intended to significantly enhance cognitive functions. |
For the cognitive training sessions, patients will be asked to play cognitive computer games involving processing speed tasks for about 15 to 30 minutes. Strong cognitive training is intended to significantly enhance cognitive functions Sham H-coil delivered rTMS sessions will be given three times per treatment visit for up to 10 visits within about 2 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete. In case of sham TMS, no actual magnetic stimulation will occur, still the participant hears the TMS sound and a skin sensation. |
|
Eksperimentell: Sham rTMS Combined with Weak Cognitive Training
Participants will receive sham H-coil delivered rTMS, as well as weak cognitive training in each treatment visit for up to 10 treatment visits within about 2 weeks. In each visit, there are three rTMS sessions and each of them is followed by a cognitive training session and a rest period, which allows the inter-rTMS-session interval to be about 30 minutes. In case of sham TMS, no actual magnetic stimulation will occur, still the participant hears the TMS sound and a skin sensation. The cognitive training includes several cognitive computer games that are meant to improve the speed and accuracy of performance--weak cognitive training may yield only modest improvements in cognitive functions. |
For the cognitive training sessions, patients will be asked to play cognitive computer games involving processing speed tasks for about 15 to 30 minutes. Weak cognitive training may yield only modest improvements in cognitive functions. Sham H-coil delivered rTMS sessions will be given three times per treatment visit for up to 10 visits within about 2 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete. In case of sham TMS, no actual magnetic stimulation will occur, still the participant hears the TMS sound and a skin sensation. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Brain microstructural integrity as indicated by white matter fractional anisotropy (FA) values as assessed by magnetic resonance imaging (MRI)
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Fractional anisotropy (FA) values will be reported. FA values range from 0 to 1 with larger values indicating greater white matter integrity. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Brain connectivity as indicated by resting-state functional connectivity (rsFC) values as assessed by functional MRI (fMRI)
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
rsFC values will be reported as a Z-score with a range of -1 to 1, with greater absolute values indicating stronger brain connectivity. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Electrophysiological response as indicated by mismatch negativity as assessed by electroencephalography (EEG)
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Mismatch negativity values will be reported in microvolts (uV). Mismatch negativity is measured by subtracting the averaged response to a set of standard stimuli from the average response to deviant stimuli, and taking the amplitude of this difference in a given timepoint. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Electrophysiological response as indicated by steady-state auditory evoked responses from electroencephalography recording (EEG)
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Steady-state auditory evoked responses will be reported. The responses are measured by calculating the ratio of the power at target frequency over power at the surrounding background frequencies. The ratio will be obtained in a given timepoint. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Cognitive insight as assessed by the Beck Cognitive Insight Scale
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Total score will be reported and ranges from 15 to 60, with a higher score indicating greater cognitive insight. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Emotion regulation as assessed by the Profile of Mood States (POMS)
Tidsramme: day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline,
|
Total score will be reported and ranges from 0 to 204, with a higher score indicating more positive emotion and mood. This outcome measure will be assessed at each of the 10 treatment visits (which are about day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline, respectively). |
day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline,
|
|
Depression as assessed by the Depression State and Trait Scale (DST) - state
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Total score of the state subscale of the DST will be reported and ranges from 0 to 72, with a higher score indicating greater depression state. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Depression as assessed by the Depression State and Trait Scale (DST) - trait
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Total score of the trait subscale of the DST will be reported and ranges from 0 to 72, with a higher score indicating greater depression trait. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Depression as assessed by the Calgary Depression Scale
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Total score of the Calgary Depression Scale will be reported and ranges from 0 to 27, with a higher score indicating greater depression. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Depression as assessed by the Beck Depression Inventory
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Total score of the Beck Depression Inventory will be reported and ranges from 0 to 63, with a higher score indicating greater depression. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Perception as assessed by the Perception State and Trait Scale - state
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
The Perception State and Trait Scale assesses alterations in the perception of audio and visual experiences. Total score ranges from 0 to 96 for the state subscale, and a higher score indicates a greater alteration of audio or visual experiences state. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Perception as assessed by the Perception State and Trait Scale - trait
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
The Perception State and Trait Scale assesses alterations in the perception of audio and visual experiences. Total score ranges from 0 to 96 for the trait subscale, and a higher score indicates a greater alteration of audio or visual experiences trait. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Hallucination as assessed by the Revised Hallucinations Scale (RHS)
Tidsramme: day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline
|
Total score will be reported and ranges from 0 to 13, with a higher score indicating greater hallucination. This outcome measure will be assessed at each of the 10 treatment visits (which are about day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline, respectively). |
day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline
|
|
Delusion as assessed by the 21-item Peters Delusion Inventory (PDI-21)
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Total score will be reported and ranges from 0 to 21, with a higher score indicating greater delusion. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Cognitive function as assessed by the Letter-Number Span subscale of the MATRICS consensus cognitive battery (MCCB)
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Total score will be reported and ranges from 0 to 24, with a higher score indicating greater cognitive function. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
|
Cognitive function as assessed by the Spatial Span subscale of the MATRICS consensus cognitive battery (MCCB)
Tidsramme: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Total score will be reported and ranges from 0 to 32, with a higher score indicating greater cognitive function. |
baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Xiaoming Du, PhD, The University of Texas Health Science Center, Houston
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- HSC-MS-23-1044 (study 3)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .